TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: MYC    
MYC Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Assessment of MYC expression

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

MYC is a proto-oncogene commonly overexpressed in many malignant neoplasms, including some B-cell lymphomas. MYC translocations are a hallmark abnormality of Burkitt lymphoma. The presence of the MYC translocation may be a helpful indicator of poor prognosis or an aggressive clinical course in diffuse large B-cell lymphoma.

Interpretation Provides information to assist in interpretation of the test results

This test does not include pathologist interpretation, only technical performance of the stain. If interpretation is required, order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.

 

The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request, call 855-516-8404.

 

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Mentzel T, Schildhaus HU, Palmedo G, Buttner R, Kutzner H: Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol. 2012;25(1):75-85

2. Faria M, Khayat A, Burbano R, Rabenhorst SH: c-MYC amplification and expression in astrocytic tumors. Acta Neuropathol. 2008;116:87-95

3. Ruzinova M, Caron T, Rodig S: Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol. 2010;34(6):882-891